

# Kongeriget Danmark

Patent application No.: PA 1999 00041

Date of filing: 15 January 1999

Applicant: Novo Nordisk A/S  
Novo Allé  
DK-2880 Bagsværd

This is to certify the correctness of the following information:

The attached photocopy is a true copy of the following information:

- The specification, claims and abstract as filed with the application on the filing date indicated above.



Patent- og

Attorney Docket No.: 5686.200-US



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 17 2000

TECH CENTER 1600/2900

In re Application of: Teng et al.

Application No.: 09/483,504

Group Art Unit: To be assigned

Filed: January 14, 2000

Examiner: To be assigned

For: Non-Peptide GLP-1 Agonists

CLAIM TO CONVENTION PRIORITY UNDER 35 U.S.C. 119


Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

In the matter of the above-identified application and under the provision of 35 U.S.C. 119, Applicants claim priority of application Serial No. 09/483,504 filed on January 14, 2000 in Danish application no. PA 1999 00041 filed on January 15, 1999. Applicants submit a duly certified copy of said foreign application.

Respectfully submitted,

Date: May 9, 2000

  
Elias J. Lambiris, Reg. No. 33,728

Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401

(212) 867-0123

609 987 5800

J. Kyparis

11. 2. 2000 2